Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability
- 1 November 2014
- journal article
- research article
- Vol. 29 (11) , 1455-1466
Abstract
Molecular and genetic investigations in endometrial carcinogenesis may have prognostic and therapeutic implications. We studied the expression of EGFR, c-Met, PTEN and the mTOR signalling pathway (phospho-AKT/phospho-mTOR/phospho-RPS6) in 69 consecutive tumours and 16 tissue microarrays. We also analysed PIK3CA, K-Ras mutations and microsatellite instability (MSI). We distinguished two groups: group 1 (grade 1 and 2 endometrioid cancers) and group 2 (grade 3 endometrioid and type II clear and serous cell cancers). We hypothesised that these histological groups might have different features. We found that a) survival was higher in group 1 with less aggressive tumours (P<0.03); b) EGFR (P=0.01), PTEN and the AKT/mTOR/RPS6 signalling pathway were increased in group 1 versus group 2 (P=0.05 for phospho-mTOR); c) conversely, c-Met was higher (P<0.03) in group 2 than in group 1; d) In group 1, EGFR was correlated with c-Met, phosphomTOR, phospho-RPS6 and the global activity of the phospho-AKT/phospho-mTOR/phospho-RPS6 pathway. In group 2, EGFR was correlated only with the phosphoAKT/phospho-mTOR/phospho-RPS6 pathway, whereas c-Met was correlated with PTEN; e) survival was higher for tumours with more than 50% PTEN-positive cells; f) K-RAS and PIK3CA mutations occurred in 10-12% of the available tumours and MSI in 40.4%, with a loss of MLH1 and PMS2 expression. Our results for difference in status between groups 1 and 2. The patients may benefit from different targeted treatments, anti-EGFR agents and rapamycin derivatives (anti-mTOR) for group 1 and an anti c-MET/ligand complex for group 2.Keywords
This publication has 35 references indexed in Scilit:
- Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung CancerClinical Lung Cancer, 2012
- Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the diseaseMolecular and Cellular Endocrinology, 2012
- Use of mutation profiles to refine the classification of endometrial carcinomasThe Journal of Pathology, 2012
- PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumorsHuman Pathology, 2011
- Clinical significance of pmTOR expression in endometrioid endometrial carcinomaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2010
- Overexpressed epidermal growth factor receptor (EGFR)‐induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen‐activated protein kinase signaling pathwayCancer, 2010
- Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virusHuman Pathology, 2009
- Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitroJournal of Cancer Research and Clinical Oncology, 2008
- PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations☆Human Pathology, 2006
- PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapyInternational Journal of Cancer, 2002